MAPK3 and breast cancer: Our finding that secretome from miR193a-3p-treated MCF-7 cells inhibited ERK1/2 and Akt phosphorylation suggests that miR193a-3p prevents the release of ERK and Akt activating proangiogenic factors from BC cells.